Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Gheorghiade M, et al. Among authors: burnett jc. J Card Fail. 2005 May;11(4):260-9. doi: 10.1016/j.cardfail.2005.03.009. J Card Fail. 2005. PMID: 15880334 Clinical Trial.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. Among authors: burnett jc jr. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Gheorghiade M, et al. Among authors: burnett jc jr. JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384438 Clinical Trial.
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Wang NC, et al. Among authors: burnett jc jr. JAMA. 2008 Jun 11;299(22):2656-66. doi: 10.1001/jama.299.22.2656. JAMA. 2008. PMID: 18544725
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: burnett jc jr. J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056. J Am Coll Cardiol. 2008. PMID: 18992654 Free article. Clinical Trial.
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: burnett jc jr. Eur Heart J. 2009 Jul;30(13):1666-73. doi: 10.1093/eurheartj/ehp144. Epub 2009 May 2. Eur Heart J. 2009. PMID: 19411662 Clinical Trial.
Effects of tolvaptan on dyspnoea relief from the EVEREST trials.
Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Pang PS, et al. Among authors: burnett jc jr. Eur Heart J. 2009 Sep;30(18):2233-40. doi: 10.1093/eurheartj/ehp253. Epub 2009 Jun 27. Eur Heart J. 2009. PMID: 19561338 Free PMC article. Clinical Trial.
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Pang PS, et al. Among authors: burnett jc jr. Am Heart J. 2011 Jun;161(6):1067-72. doi: 10.1016/j.ahj.2011.02.027. Am Heart J. 2011. PMID: 21641352 Clinical Trial.
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Costello-Boerrigter LC, et al. Among authors: burnett jc jr. Am J Physiol Renal Physiol. 2006 Feb;290(2):F273-8. doi: 10.1152/ajprenal.00195.2005. Epub 2005 Sep 27. Am J Physiol Renal Physiol. 2006. PMID: 16189291 Free PMC article. Clinical Trial.
639 results